FDA Asks Genervon To Release ALS Drug Trial Data As Pressure From Patients Builds
This article was originally published in The Pink Sheet Daily
Executive Summary
In response to calls from patients and others about GM604, FDA issued a public statement calling on the company to release full clinical trial data for its investigative amyotrophic lateral sclerosis drug, which recently completed a Phase IIa trial.